CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods ...

Also within the antibody field the cell-free technology has gained considerable attention with respect to the clinical research pipeline including antibody discovery and production. Besides the ...

Late-breaker poster presentation at the inaugural AACR IO underscores potential of VCR-036, a novel PD-1/CTLA-4 VHH antibody for treatment of solid tumors Being developed to solve limitations due to ...

About VINCOBODIES VINCOBODIES are an advancement in antibody engineering ... the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology.

AUSTIN, Texas, February 20, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody ...

In this study, we applied an advanced large language model (LLM), the Pro-PRIME model, to improve the alkali resistance of a representative antibody, a VHH antibody capable of binding to growth ...